Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 101

Similar articles for PubMed (Select 19620786)

1.

Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells.

Ivanov A, Beers SA, Walshe CA, Honeychurch J, Alduaij W, Cox KL, Potter KN, Murray S, Chan CH, Klymenko T, Erenpreisa J, Glennie MJ, Illidge TM, Cragg MS.

J Clin Invest. 2009 Aug;119(8):2143-59. doi: 10.1172/JCI37884. Epub 2009 Jul 20.

2.

Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway.

Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, Huang P, Cragg MS, Illidge TM.

Blood. 2012 Apr 12;119(15):3523-33. doi: 10.1182/blood-2011-12-395541. Epub 2012 Feb 21.

3.

Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies.

Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, Shimada K, Chan CH, Tutt A, Beers SA, Glennie MJ, Cragg MS, Illidge TM.

Blood. 2011 Apr 28;117(17):4519-29. doi: 10.1182/blood-2010-07-296913. Epub 2011 Mar 4.

4.

Type II anti-CD20 mAb-induced lysosome mediated cell death is mediated through a ceramide-dependent pathway.

Ren H, Zhang C, Su L, Bi X, Wang C, Wang L, Wu B.

Biochem Biophys Res Commun. 2015 Feb 20;457(4):572-7. doi: 10.1016/j.bbrc.2015.01.026. Epub 2015 Jan 17.

PMID:
25603047
5.

CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts.

Chan HT, Hughes D, French RR, Tutt AL, Walshe CA, Teeling JL, Glennie MJ, Cragg MS.

Cancer Res. 2003 Sep 1;63(17):5480-9.

6.

Engaging the lysosomal compartment to combat B cell malignancies.

Grønbaek K, Jäättelä M.

J Clin Invest. 2009 Aug;119(8):2133-6. doi: 10.1172/JCI40259. Epub 2009 Jul 20.

7.

Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Loisel S, André PA, Golay J, Buchegger F, Kadouche J, Cérutti M, Bologna L, Kosinski M, Viertl D, Delaloye AB, Berthou C, Mach JP, Boumsell L.

Mol Cancer. 2011 Apr 19;10:42. doi: 10.1186/1476-4598-10-42.

8.

Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.

Liu C, DeNardo G, Tobin E, DeNardo S.

Cancer Biother Radiopharm. 2004 Oct;19(5):545-61.

PMID:
15650447
9.
10.

BM-ca is a newly defined type I/II anti-CD20 monoclonal antibody with unique biological properties.

Nishida M, Uematsu N, Kobayashi H, Matsunaga Y, Ishida S, Takata M, Niwa O, Padlan EA, Newman R.

Int J Oncol. 2011 Feb;38(2):335-44. doi: 10.3892/ijo.2010.864. Epub 2010 Dec 6.

PMID:
21152859
11.

Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death.

Golay J, Bologna L, André PA, Buchegger F, Mach JP, Boumsell L, Introna M.

Blood. 2010 Oct 28;116(17):3372-3; author reply 3373-4. doi: 10.1182/blood-2010-06-289736. No abstract available.

12.

Membrane microdomain sphingolipids are required for anti-CD20-induced death of chronic lymphocytic leukemia B cells.

Hammadi M, Youinou P, Tempescul A, Tobón G, Berthou C, Bordron A, Pers JO.

Haematologica. 2012 Feb;97(2):288-96. doi: 10.3324/haematol.2011.051938. Epub 2011 Nov 4.

13.

Homotypic aggregation of human cell lines by HLA class II-, class Ia- and HLA-G-specific monoclonal antibodies.

Odum N, Ledbetter JA, Martin P, Geraghty D, Tsu T, Hansen JA, Gladstone P.

Eur J Immunol. 1991 Sep;21(9):2121-31.

PMID:
1889460
14.

Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.

van der Kolk LE, de Haas M, Grillo-López AJ, Baars JW, van Oers MH.

Leukemia. 2002 Apr;16(4):693-9.

15.

Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.

Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, Golay J.

J Immunol. 2011 Mar 15;186(6):3762-9. doi: 10.4049/jimmunol.1000303. Epub 2011 Feb 4.

16.

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.

Gupta P, Goldenberg DM, Rossi EA, Cardillo TM, Byrd JC, Muthusamy N, Furman RR, Chang CH.

Blood. 2012 Apr 19;119(16):3767-78. doi: 10.1182/blood-2011-09-381988. Epub 2012 Jan 23.

17.

Novel humanized anti-CD20 monoclonal antibodies with unique germline VH and VL gene recruitment and potent effector functions.

Nishida M, Teshigawara K, Niwa O, Usuda S, Nakamura T, Ralph P, Newman R, Padlan EA.

Int J Oncol. 2008 Jun;32(6):1263-74.

PMID:
18497988
18.

New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.

Robak T, Robak E.

BioDrugs. 2011 Feb 1;25(1):13-25. doi: 10.2165/11539590-000000000-00000. Review.

PMID:
21090841
19.

Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation.

Beers SA, Chan CH, James S, French RR, Attfield KE, Brennan CM, Ahuja A, Shlomchik MJ, Cragg MS, Glennie MJ.

Blood. 2008 Nov 15;112(10):4170-7. doi: 10.1182/blood-2008-04-149161. Epub 2008 Jun 26.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk